![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Patient-Reported Symptom Outcomes Following DTG/3TC Use in
a Test-and-Treat Setting: Results From the STAT Study
|
|
|
Glasgow 2022 Oct 23-26
Alan Oglesby,1 Jessica E. Matthews,1 Konstantinos Angelis,2 Peter A. Leone,1 Michael Cupo,3 Brian R. Wynne,1 Deanna Merrill,1 Christopher Nguyen,1
Jan van Wyk,4 Andrew R. Zolopa1,5
1ViiV Healthcare, Durham, NC, USA; 2GSK, Brentford, UK; 3GSK, Upper Providence, PA, USA; 4ViiV Healthcare, Brentford, UK; 5Stanford University, Palo Alto, CA USA
![1028221](../images/102822/102822-10/1028221.gif)
![1028222](../images/102822/102822-10/1028222.gif)
![1028223](../images/102822/102822-10/1028223.gif)
![1028224](../images/102822/102822-10/1028224.gif)
![1028225](../images/102822/102822-10/1028225.gif)
![1028226](../images/102822/102822-10/1028226.gif)
![1028227](../images/102822/102822-10/1028227.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|